Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Parkinson's Disease
Sort By
Newest First
1 / 1
1 / 1
Announcement
AbbVie Announces Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
AbbVie
PR-12-24-NI-134
Dec 11, 2024
Neurodegenerative Disease Clinical Trials
Preparing for Growth in Neurodegenerative Treatment Opportunities: How Clinical Teams can Best Position Study Design and Strategy to Reach Study Participants
John Hamlet; Christine Martino, MPM; Sabine Krofczik-Wilhelm, Ph.D.; Alberto Lledó, M.D., Ph.D.
PPD, part of Thermo Fisher Scientific
PAO-09-022-CL-09
Sep 27, 2022
Plant-Inspired Drug Discovery
Unlocking the Therapeutic Potential of Plant-Inspired Minimum Essential Mixtures
Andrea Small-Howard, Ph.D.
Gb Sciences, Inc.
PAO-08-022-CL-01
Sep 06, 2022
Parkinson's Disease Research
Gb Sciences to Begin Dosage Study for Its Novel Parkinson's Disease Formulations at the University of Lethbridge
Gb Sciences, Inc.
PR-M04-22-08
Apr 12, 2022
Neurodegenerative Diseases
Pioneering Nanocatalysis to Revolutionize Treatments for Neurodegenerative Diseases
Rob Etherington
PAO-01-22-CL-06
Mar 12, 2022
Parkinsons's Disease
Novel Computational Approaches to Parkinson's Disease Drug Development
Eric Richman
PTV-08-21-CL-002
Aug 18, 2021
Brain Organoids
Leveraging Organoids to Address Neurodegenerative Diseases
OrganoTherapeutics
PAO-04-22-R221-66-400
Apr 29, 2021
Stem Cells
Changing the Paradigm of Stem Cell Technology
Sandy Solmon
Celavie Biosciences
PAP-Q4-20-CL-008
Dec 09, 2020
Drug Repositioning
A Therapeutic Strategy for Neurological Disorders
Franck Mouthon; Mathieu Charvériat, Ph.D.
Theranexus
PAP-Q2-20-CL-016
Jul 01, 2020
Cell and Gene Therapy
One-time Treatment Generates New Neurons, Eliminates Parkinson's Disease in Mice
University of California San Diego
PR-M06-20-NI-036
Jun 30, 2020
FDA Approval
FDA Approves New Add-on Drug to Treat Off Episodes in Adults with Parkinson’s disease
U.S. Food & Drug Administration
PR-M08-19-NI-090
Aug 30, 2019
Next-Generation Therapy
Smart Brain Stimulators: Next-Gen Parkinson’s Disease Therapy
University of Houston
PR-M07-19-NI-077
Jul 30, 2019
Collaboration
New Collaboration Targets Parkinson’s Disease
David Alvaro, Ph.D.
Pharma's Almanac
PAO-M03-19-NI-005
Mar 05, 2019
Phase 3 Study
Britannia Pharmaceuticals Ltd: Phase 3 TOLEDO Study Shows Apomorphine Infusion Provides Effective Relief of Persistent Motor Fluctuations in Parkinson's Disease
Britannia Pharmaceuticals
PR-M08-18-NI-043
Aug 13, 2018
